TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18600190
Drug: MMRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV vaccine (Priorix-Tetra; GlaxoSmithKline Biologicals) - 2 doses administered 42 days apart (MMRV group; N = 732)
Study: 18600190
Drug: MMR vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine (Priorix) coadministered with varicella vaccine (Varilrix) - 1 dose followed by a second dose of MMR vaccine 42 days later (MMR + V group; N = 238)
Study: 6214437
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment with tetracycline (total dose: 1st month 28.5 g; 2nd and 3rd months 15.0 g)
Study: 30476254
Drug: Reducing calcineurin
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reducing calcineurin inhibitor (CNI first)
Study: 28597604
Drug: Lesinurad 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesinurad 400 mg daily plus febuxostat 80 mg/day
Study: 28597604
Drug: Lesinurad 200
Normalized name: lesinurad 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesinurad 200 mg daily plus febuxostat 80 mg/day
Study: 28597604
Drug: Febuxostat 80
Normalized name: febuxostat 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 80 mg/day alone
Study: 28597604
Drug: Lesinurad 200
Normalized name: lesinurad 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesinurad 200 mg and 400 mg plus febuxostat
Study: 25846114
Drug: NO3 (‐)‐rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO3 (‐)‐rich beetroot juice (BR; 140 mL day(‐1); 12.8 mmol of NO3 (‐))
Study: 25846114
Drug: NO3 (‐)‐depleted
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO3 (‐)‐depleted beetroot juice (PL; 140 mL day(‐1); 0.08 mmol NO3 (‐))
Study: 10078674
Drug: Sufentanil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (10 microg) + Transdermal Nitroglycerine (5 mg/day)
Study: 10078674
Drug: Sufentanil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (10 microg) + Transdermal Placebo
Study: 10078674
Drug: Transdermal Nitroglycerine
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal Nitroglycerine (5 mg/day) + Spinal Saline
Study: 10078674
Drug: Spinal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal Saline + Transdermal Placebo
Study: 24842179
Drug: BoNT‐A injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT‐A injection (second dose)
Study: 19756479
Drug: Endpoint insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endpoint insulin dose
Study: 19756479
Drug: End-of-study insulin
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-of-study insulin dose
Study: 19756479
Drug: Contact frequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contact frequency in DPP-4 inhibitor trials
Study: 16119485
Drug: PCEA +
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA + CEI (continuous epidural infusion of ropivacaine 0.15% with sufentanil 0.75 microg/ml at 2 ml/h)
Study: 12377832
Drug: Nasal CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal CPAP treatment for 3 weeks in patients with SDB (AHI >= 5)
Study: 12377832
Drug: Nasal CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal CPAP treatment for 3 weeks in patients without SDB (AHI < 5)
Study: 8110550
Drug: Continuous i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous i.v. infusion (group A: 1.25 u. h‐1)
Study: 8110550
Drug: Direct i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct i.v. bolus administration of 10 u. every 2 h (group B: 10 u./2 h)
Study: 3044040
Drug: iopamidol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopamidol (50 ml)
Study: 3044040
Drug: iopamidol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopamidol (100 ml)
Study: 3044040
Drug: diatrizoate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: diatrizoate (50 ml)
Study: 20688800
Drug: IPT in
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPT in combination with anti-depressant medication
Study: 20688800
Drug: IPT in
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPT in combination with pill-placebo
Study: 20688800
Drug: Standard antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antidepressant therapy (medication, psychotherapy, or both)
Study: 18765878
Drug: Sodium antimony
Normalized name: Sodium antimonyl gluconate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium antimony gluconate (SAG) at a dosage of 20 mg/kg given deep intramuscular injections for 28 days (Group A)
Study: 18765878
Drug: Sodium antimony
Normalized name: Sodium antimonyl gluconate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium antimony gluconate (SAG) for patients whose amastigotes were resistant or withdrew due to toxicity, treated with amphotericin B (AMB) at 1 mg/kg daily for 20 days
Study: 18765878
Drug: Total expenditure
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total expenditure on treatment
Study: 8853536
Drug: Palliative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palliative radiotherapy (short-course fractionated treatment)
Study: 8853536
Drug: Palliative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palliative radiotherapy (with 5HT3 antagonists)
Study: 6653921
Drug: Domperidone, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone, 10 mg intravenously
Study: 27965488
Drug: Rebamipide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide (100 mg TID for 21 days)
Study: 27965488
Drug: Betamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (4 mg/mL biweekly for 4 weeks)
Study: 21756151
Drug: Q-switched alexandrite
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-switched alexandrite laser treatment with a 3-mm spot size
Study: 21756151
Drug: Q-switched alexandrite
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-switched alexandrite laser treatment with a 4-mm spot size
Study: 21756151
Drug: Q-switched alexandrite
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-switched alexandrite laser treatment with a 4-mm spot size (lower fluence)
Study: 21756151
Drug: Q-switched alexandrite
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-switched alexandrite laser treatment
Study: 20847757
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (20 mg/kg daily)
Study: 9846923
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream 5% (1 g applied for 60-70 min)
Study: 9846923
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 g applied for 60-70 min)
Study: 8124787
Drug: Sodium restriction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium restriction treatment
Study: 2801550
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg daily (Control)
Study: 2801550
Drug: Urokinase 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase 3 x 10(6) U intravenously over 30 minutes followed by heparin
Study: 780378
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day ripazepam (CI-683)
Study: 780378
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day ripazepam (CI-683)
Study: 17609906
Drug: Astragalus Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus Injection (AI) plus Stanozolol (2 mg three times a day)
Study: 17609906
Drug: Stanozolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stanozolol (2 mg three times a day)
Study: 17609906
Drug: Astragalus Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus Injection (AI) plus Stanozolol
Study: 24782199
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg IV
Study: 29318244
Drug: Freeze-dried strawberry
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried strawberry (24 g d‐1, equivalent to 2 cups of fresh strawberries)
Study: 24376273
Drug: Parenteral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Parenteral artesunate
Study: 22412067
Drug: Parenteral quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral quinine
Study: 15848600
Drug: ACEI/ARB therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI/ARB therapy (started within 14 months after surgery)
Study: 14624284
Drug: Ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (4 mg bid p.o.)
Study: 10912979
Drug: Nitrofurantoin 100
Normalized name: nitrofurantoin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin 100 mg (two doses)
Study: 6517812
Drug: iohexol 300
Normalized name: IOHEXOL 300MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol 300 I/ml
Study: 2914116
Drug: ioxaglate 320
Normalized name: ioxaglate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ioxaglate 320 mg I/ml
Study: 30025534
Drug: Full intervention
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full intervention (prescription review and league tables plus authorised feedback letter)
Study: 30025534
Drug: Partial intervention
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial intervention (prescription review and league tables)
Study: 30025534
Drug: Control (prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (prescription review only)
Study: 18190597
Drug: Lack of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lack of awareness of service availability (32.9%) was the most common reason for not seeking treatment.
Study: 1579327
Drug: hCG administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG administration (2500 IU on days 3, 6, and 9 after ovulatory dose of 10,000 IU hCG)
Study: 1579327
Drug: Non-treatment cycles
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment cycles (no luteal phase support)
Study: 1579327
Drug: Non-treatment cycles
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment cycles
Study: 3907322
Drug: Diltiazem (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (360 mg/day, administered 2 times a day)
Study: 31515555
Drug: Capecitabine +
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine + oxaliplatin + bevacizumab or another reintroduction treatment
Study: 30099829
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of cortisol
Study: 18332313
Drug: Voriconazole, 1%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole, 1%, eyedrops administered hourly for 4 doses
Study: 18332313
Drug: Voriconazole, 1%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole, 1%, eyedrops administered every 6 hours for 3 days
Study: 15973769
Drug: Chronic hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic hepatitis B patients without lamivudine treatment
Study: 1699989
Drug: Hydroxyzine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine (100 mg/day)
Study: 1699989
Drug: Terfenadine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (120 mg/day)
Study: 31605900
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SH + FR
Study: 24164645
Drug: Intensive oral
Normalized name: Uricalm Intensive Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive oral hygiene regimen including dental prophylaxis at baseline and oral hygiene instructions at baseline, 4 and 8 weeks.
Study: 15377133
Drug: Terminalia arjuna
Normalized name: terminalia arjuna
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terminalia arjuna (500 mg q8h)
Study: 11482921
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of abciximab and stenting as an adjunct to PTCA
Study: 9683836
Drug: Ceftazidime +
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime + amikacin + teicoplanin (6 mg/kg once a day)
Study: 9683836
Drug: Ceftazidime +
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime + amikacin + vancomycin (30 mg/kg/day every 6 h)
Study: 7810811
Drug: Halofantrine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine (24 mg/kg or 72 mg/kg)
Study: 3175849
Drug: Intracavitary high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavitary high-dose rate iridium irradiation
Study: 3175849
Drug: Intracavitary high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavitary high-dose rate iridium irradiation (younger patients)
Study: 3175849
Drug: Intracavitary high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavitary high-dose rate iridium irradiation (older patients, 70 years and more)
Study: 3175849
Drug: Intracavitary high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavitary high-dose rate iridium irradiation (tumor grading 1)
Study: 3175849
Drug: Intracavitary high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavitary high-dose rate iridium irradiation (tumor grading 2 and 3)
Study: 31953583
Drug: Positive risk
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive risk encouragement (e.g., 'You are cool if you continue')
Study: 31953583
Drug: Negative risk
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative risk encouragement (e.g., 'You are a softy if you do not continue')
Study: 28688742
Drug: Clozapine 300mg/day
Normalized name: CLOZAPINE 300MG/DAY TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 300mg/day (monotherapy)
Study: 8723572
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 600 IU/kg administered intravenously twice weekly for 3 weeks (in conjunction with oral iron supplementation)
Study: 1691132
Drug: Cyclic alternating
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic alternating drugs (DNR + VCR + Ara-C)
Study: 508556
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg three times daily dipyridamole + 180 mg ASA
Study: 508556
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg three times daily dipyridamole + 120 mg ASA daily
Study: 508556
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg dipyridamole three times daily + 60 mg ASA
Study: 508556
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of dipyridamole and ASA
Study: 508556
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of ASA in combination with dipyridamole
Study: 27989693
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of artificial tear containing dextran 70 (1mg/ml) and hypromellose (3mg/ml)
Study: 23645328
Drug: Prospective ECG-triggered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prospective ECG-triggered sequential CCTA
Study: 19723649
Drug: Lapuleucel-T (APC8024)
Normalized name: Lapuleucel-t
DrugBank: Lapuleucel-t (DB19117)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapuleucel-T (APC8024) administered via leukapheresis and infusions in weeks 0, 2, and 4.
Study: 10463739
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (nadroparin) - one daily subcutaneous injection, dosage adapted to body-weight
Study: 10463739
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (nadroparin)
Study: 7640875
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (120 mg single dose or 90 mg daily for 23 days)
Study: 27716162
Drug: Enhanced cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced cognitive behavioral therapy (CBT-E)
Study: 25425451
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (metformin followed by sulfonylurea and glargine insulin)
Study: 23171911
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of hydrocortisone orally
Study: 23171911
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of hydrocortisone orally in BPD patients with co-morbid PTSD
Study: 23171911
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of hydrocortisone orally in BPD patients with co-morbid MDD
Study: 11758322
Drug: Simultaneous bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous bolus injection of 2% lidocaine 2 ml with infusion of propofol
Study: 11758322
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of saline 2 ml, 10 s before propofol infusion
Study: 11758322
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of lidocaine 2 ml, 10 s before propofol infusion
Study: 11758322
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of saline 2 ml, 10 s before propofol infusion (control group)
Study: 11758322
Drug: Simultaneous bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous bolus injection of lidocaine with propofol
Study: 2928745
Drug: Rinsing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinsing with test agents after brushing with amine fluoride dentifrice (Elmex)
Study: 28525984
Drug: Probiotic Lactobacillus
Normalized name: Probiotic Lactobacillus Acidophilus Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Lactobacillus Fermentum CECT5716, daily for 8 weeks
Study: 23149845
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B therapy (FAB/LMB 96 study)
Study: 18285717
Drug: Cirrhotic patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cirrhotic patients not responding or relapsing after treatment
Study: 10637531
Drug: VOCs at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: VOCs at 25 mg/m(3) for four hours
Study: 10637531
Drug: VOCs at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: VOCs at 50 mg/m(3) for four hours
Study: 8317063
Drug: Oral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of a polyethylene glycol solution (out-patient)
Study: 8317063
Drug: Oral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of a polyethylene glycol solution (in-patient)
Study: 16204433
Drug: Ketanserin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (40 mg)
Study: 2446061
Drug: Ketanserin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (40 mg) plus Hydrochlorothiazide (25 mg)
Study: 30325939
Drug: AL-335 800
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL-335 800 mg QD in non-cirrhotic, GT1-4-infected subjects
Study: 30325939
Drug: AL-335 800
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL-335 800 mg QD in GT1-infected cirrhotic subjects
Study: 30325939
Drug: AL-335 (100-1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL-335 (100-1,200 mg) in healthy volunteers
Study: 30325939
Drug: AL-335 (400,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL-335 (400, 800, 1,200 mg) in HCV-infected subjects
Study: 30325939
Drug: AL-335 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL-335 (400 mg) in fed state
Study: 30325939
Drug: AL-335 (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL-335 (1,200 mg) in fasted state
Study: 28391393
Drug: NZBC extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NZBC extract 600 mg day-1
Study: 28391393
Drug: NZBC extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NZBC extract 900 mg day-1
Study: 28391393
Drug: NZBC extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NZBC extract 300 mg day-1
Study: 28391393
Drug: No dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: No dose
Study: 26052874
Drug: Clinician feedback
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician feedback intervention (CCFS) consisting of weekly performance feedback to clinicians and a clinical feedback report.
Study: 23411609
Drug: Linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 5 mg daily
Study: 22332579
Drug: Oral glucosamine
Normalized name: glucosamine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucosamine hydrochloride (1.44 g daily) + intraarticular hyaluronate injection
Study: 14580925
Drug: BAY 19-8004
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 19-8004 (5 mg once daily)
Study: 29526243
Drug: Standard cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cancer treatment plus the ANITA program (integrative Tai Chi program including peer support, health education, and Tai Chi Ruler exercise)
Study: 29526243
Drug: Standard cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cancer treatment alone
Study: 22648913
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg (test formulation)
Study: 22648913
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg (reference formulation)